ArticleScientific reports2025
Epitope mapping strategies for immunogenicity mitigation in streptokinase therapeutics: an in-silico study.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Fibrinolytic drugs, particularly streptokinase (SK), are crucial for the management of blood clotting disorders. However, SK's bacterial origin triggers immune responses that generate neutralizing antibodies, diminishing its effectiveness. This study aimed to identify and eliminate B-cell epitopes in SK to reduce its immunogenicity through targeted point mutations. By utilizing advanced in silico tools, we predicted the SK structure and identified both linear and conformational B-cell epitopes. Hot spot residues within these epitopes were identified using a combination of epitope prediction algorithms, molecular dynamics and docking simulations, conservancy analysis, and propensity scales. Our innovative approach suggested key antigenic residues E53, D174, and S258 that were strategically mutated to minimize immunogenicity. Immuno-informatics tools indicated that the modified SK could exhibit a significantly reduced immunogenic profile. Molecular dynamics simulations supported the structural integrity of the modified SK, and docking studies suggested its preserved interaction potential with plasminogen. Our results propose that the mutein E53M-D174M-S258W could reduce the immunogenic response, thus improving its therapeutic potential.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.